PA
CLMT icon

Parallel Advisors’s Calumet Specialty Products CLMT Stock Holding History

Parallel Advisors’s Portfolio CLMT Stock Details CLMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8
Closed -$159 – 3856
2025
Q4 		$159 Hold
8
– – ﹤0.01% 3526
2025
Q3 		$146 Hold
8
– – ﹤0.01% 3465
2025
Q2 		$126 Buy
+8
New +$102 ﹤0.01% 3448

Other funds holding CLMT

TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WDOM
Wasserstein Debt Opportunities Management New York $189M AUM 169.75% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AAA
Adams Asset Advisors Dallas, Texas $882M AUM 42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Parallel Advisors's CLMT Position: Q1 2026 in Review

Parallel Advisors sold out of Calumet Specialty Products (CLMT) in Q1 2026, closing a stake of 8 shares — an estimated $159 sold.

Parallel Advisors first reported a position in CLMT in Q2 2025 and held it in 3 quarters. The position peaked at $159 in Q4 2025. 180 funds tracked by Wall St. Rank hold CLMT as of Q1 2026.

  • Parallel Advisors reported no remaining Calumet Specialty Products position as of Q1 2026 after selling out during the quarter.
  • Parallel Advisors sold 8 Calumet Specialty Products shares in Q1 2026, an estimated $159.
  • Parallel Advisors first reported a position in Calumet Specialty Products in Q2 2025 and held it in 3 quarters.
  • Parallel Advisors's Calumet Specialty Products position peaked at $159 in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Calumet Specialty Products as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.